Correction to “Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome”

Figure 1 Inhibition of AMPK abolished the beneficial effects of teneligliptin against high glucose in cardiomyocytes. Primary cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (5 μmol/L) and compound C (10 μM). A: Levels of p-AMPK. ^aP < 0.05 vs control group; ^bP < 0.05 vs high glucose 30 mmol/L group; ^cP < 0.05 vs high glucose 30 mmol/L + teneligliptin 5 μmol/L group, n = 5.